

MED DEVICE MONTHLY

"The RW Search Company Newsletter on the latest Med-Tech developments"



ABIOMED BUYS PRECARDIA TO BAG HEART FAILURE DEVICE

Earlier this month Abiomed acquired preCARDIA to gain control of an investigational treatment for acute decompensated heart failure that has a breakthrough designation from the FDA.

PreCARDIA is developing a minimally invasive, catheter-based system designed to reduce the time heart failure patients spend in hospital and improve quality of life by delivering programmed intermittent occlusion of the superior vena cava.



Xenco's Spinal holographic surgery simulation

Xenco Medical have launched HooMedX, a holographic surgery simulation platform without spectacles that allows users to simulate entire spinal surgery in holographic space without the need for headgear or spectacles.

A simulation platform integrated with a looking glass light field display instantly transforms DICOM data, such as CT and MRI scans, into detailed, interactive holographic reconstructions.

CEO SPOTLIGHT - GRAEME L. SMITH


As of June 2021, Graeme L. Smith has been appointed as CEO of Lightpoint Medical, a world-leader in developing miniaturized imaging and sensing tools for intra-operative cancer detection and robot.

Graeme is joining the team at an exciting time, following their market clearance in the US, UK, EU and Australia for their new miniature surgical probe; Lightpoint's SENSEI® technology is the first approved gamma probe for minimally-invasive surgery

Graeme is a seasoned Med Tech industry executive with nearly three decades of experience in driving profitable business growth at global medical device companies - five of those being start ups that have gone on to sell to larger companies. Graeme sees potential in Lightpoint's product. As per his introductory interview with Lightpoint, he states; "my experience is pushing on into strong commercial activities, taking devices from start-up phase after they've gone through regulatory processes"

We are excited to witness Graeme's aid of Lightpoint Medical in their expansion, and it will be fascinating to watch the company continue to innovate in an increasingly competitive market.





2 MED-TECH START-UPS TO WATCH



NEURENT MEDICAL: an Irish startup that manufactures non-surgical treatments for sinus diseases. Its medical device, known as the NEUROMARK Rhinitis Neurolysis Therapy disrupts hyperactive parasympathetic nerves to cure chronic rhinitis.

Neurent was founded in 2015 by Mr Shields and chief technology officer David Townley as a spinout from the BioInnovate Ireland programme at the National University of Ireland, Galway.



FORSIGHT ROBOTICS: an Israel-based medical device startup founded in 2020 by Moshe Shoham Ph. D., who previously founded Mazor Robotics, which was acquired by Medtronic for \$1.6 billion.

Foresight manufactures and designs surgical robotic platforms and uses data analytics to improve ophthalmic surgery. They achieve this by combining state-of-the-art robotic microsurgical technology, advanced visualization technologies, and next-generation cognitive computing methods.

ORTHOPAEDIC FOCUS: SPENTYS

Spentys are a Belgian start-up; reinventing orthopaedics by offering Orthoses immobilisation devices through 3D scanning, 3D modeling and 3D printing technologies, tailored to each patient.



These devices are fitted externally to support the musculoskeletal system. They are much lighter and more breathable than traditional devices, and due to their flexibility, they are easy to remove and replace, allowing adjustments to be made throughout the healing process if required. Without patients having to start over with a new device, they save valuable time, costly material, and unnecessary waste.

With their advances in imaging technology, Spentys enable healthcare providers to act faster and provide their patients with a much more comfortable, customized solution - we are definitely excited to witness how they continue to progress in this sector.





DePuy Synthes launches next-gen clavicle plate system

J&J unit DePuy Synthes announced that it launched the 2.7mm variable angle locking compression plate clavicle plate system.



The new system offers plate shapes that reflect the correlation between the patient's stature and clavicle size to match the bow and contour of the clavicle.

It does this while accommodating a wide range of anatomic variability of the clavicle with thinner plates, providing a more accurate plate-to-bone fit.

PHILLIPS recall sleep apnea device

Due to possible toxic exposure, Phillips pulled its sleep Apnea devices from the market in India, which posed serious health risks.

Philips has produced millions of devices that use the polyester-based polyurethane (PE-PUR) sound-reducing foam and determined degraded foam may be ingested by the user.

This abatement foam can degrade and emit small particles that irritate airways, and may also be toxic & carcinogenic.

CANCER TECH: BREAKTHROUGH DEVICES

Cancer tech has recently been dominating the med-device sector, with a batch of investigational devices, useful in detecting the early stages of cancer, recently gaining FDA approval. Here are three that I find to be particularly exciting & progressive within this field:



Viome: Their mRNA product is designed to diagnose oral and throat cancer in saliva samples. The AI-powered diagnostic analyses messenger RNA in saliva samples to generate insights into gene expression. In doing so, Viome creates a screening test that improves on current approaches to the diagnosis of oral and throat cancer.



DermaSensor: The DermaSensor device helps primary care providers detect skin cancer. Healthcare providers apply the tip of the device to a lesion that they suspect may be cancerous. The device sends out light and captures the wavelengths that bounce back off their skin.



OncoRes Medical: A Medical landed a breakthrough designation for its own cancer-detecting device, the quantitative Micro-Elastography Imaging system. This Australian MedTech company is developing the device to reduce the need for re-excision surgeries to remove breast cancer tissue missed in the initial procedure.